Arcadia Consumer Healthcare is a portfolio company of Avista Capital Partners. Avista invests in leading healthcare companies to drive growth and build lasting value. To learn more about Avista, please visit Avistacap.com
Chairman of the Board
Robert O’Neil is an operating executive at Avista Capital Partners. Mr. O’Neil was retained by Avista Capital Partners in 2015. Mr. O’Neil has more than 35 years of operational and strategic business leadership experience and a proven track record of building healthcare businesses in the pharmaceutical and consumer sectors. Most recently, he was Worldwide Vice President of Business Development for Johnson & Johnson’s Consumer Group of Companies. Mr. O’Neil held a variety of roles at Johnson & Johnson over a 20-year career with the company. Concurrent with his most recent position, he was a member of the Consumer Group Operating Committee and a Board Member for the Johnson & Johnson Development Corp. Previously, he was Vice President, Business Development, for Johnson & Johnson’s Pharmaceutical Group from 1994 to 2002. From 1991 to 1993, Mr. O’Neil was Senior Vice President, Sales, Marketing, New Product Development, for Ortho McNeil Pharmaceutical (a fully-owned company of Johnson & Johnson). He was also a member of the Ortho McNeil Pharmaceutical Management Board. Prior to that role, Mr. O’Neil held various leadership positions in sales and marketing with the company beginning in 1974.
Mr. O’Neil received a bachelor’s degree from the Stillman School of Business at Seton Hall University and an M.B.A. from the Tobin College of Business at St. John’s University. Mr. O’Neil currently serves as Chairman of the Board of Arcadia Consumer Healthcare and as a Director of OptiNose (NASDAQ: OPTN) and previously served as a Director of Trimb Healthcare.
David Burgstahler is the Managing Partner and Co-Chief Executive Officer of Avista Capital Partners. Prior to co-founding Avista Capital Partners in 2005, Mr. Burgstahler was a Partner of DLJ Merchant Banking Partners and Head of Healthcare. Mr. Burgstahler was at DLJ Investment Banking from 1995 to 1997 and DLJMB from 1997 to 2005. Prior to joining DLJ, he worked at McDonnell Douglas (now Boeing) from 1987 to 1990 and Andersen Consulting (now Accenture) from 1991 to 1993.
Mr. Burgstahler received a B.S. in Aerospace Engineering from the University of Kansas and an M.B.A. from Harvard Business School.
Mr. Burgstahler currently serves as a Director of Arcadia Consumer Healthcare, Cosette Pharmaceuticals, Inform Diagnostics, Osmotica Pharmaceuticals (Nasdaq: OSMT), United BioSource Corporation and other private boards. He previously served on the boards of AngioDynamics (Nasdaq: ANGO), Armored AutoGroup, BioReliance, ConvaTec Group, Focus Diagnostics, INC Research Holdings (Nasdaq: INCR), Lantheus Holdings (Nasdaq: LNTH), MPI Research, Inc., Strategic Partners, Visant, Warner Chilcott (Nasdaq: WCRX) and WideOpenWest (NYSE: WOW). Mr. Burgstahler is also a Trustee of the Trinity School in New York City.
Peter Caldini has over 25 years of experience in the consumer healthcare industry with multinationals Pfizer, Bayer, and Wyeth. He has extensive global commercial experience having led business operations across North America, EMEA, LATAM, and AsiaPac. Most recently, Peter was the Regional President of North America for Pfizer Consumer Healthcare (PCH). He was responsible for all the commercial operations for the US and Canada, a $2 billion business. Prior to the North America President role, Peter was the Regional President of EMEA for PCH. The business represented $600 million in net revenue and had over 850 colleagues. At Bayer, Peter held various roles with increasing responsibility. Most notably, Peter led the emerging markets cluster in EMEA (Turkey, Middle East, CIS, Maghreb, and all of Africa). He was also the Global Head of the Nutritionals Strategic Business Unit and the interim GM of China for Bayer. Peter holds a masters degree in International Economics and Management from SDA Bocconi in Milan, and an MBA from Northeastern University in Boston. He received his Bachelor of Arts in Political Science from Boston University. He has US and Italian citizenship and speaks English, Spanish, and Italian.
Robert Girardi is a Partner at Avista Capital Partners. Mr. Girardi joined Avista Capital Partners in 2010. Prior to joining Avista, Mr. Girardi was a Senior Associate at Quadrangle Group where he focused on private equity investments in the media and communications industries. Prior to joining Quadrangle, he was an Associate at Bear Stearns Merchant Banking where he focused on private equity investments across a range of industries. He also worked as an Analyst in the investment banking division at J.P. Morgan.
Mr. Girardi received a B.S. with highest distinction in business administration from the University of North Carolina at Chapel Hill and an M.B.A. with honors from the Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He currently serves as a Director of Arcadia Consumer Healthcare, GCM Holding Corporation, and United BioSource Corporation and previously served as a Director of DataBank Holdings, MPI Research, Inc and Telular Corporation.
Alex Yu is a Principal at Avista Capital Partners. Mr. Yu joined Avista Capital Partners in 2017. Prior to joining Avista, Mr. Yu worked in the Private Equity Group at Goldman Sachs. Prior to joining Goldman Sachs, he worked as an Associate at Fenway Partners and as an Analyst in the Technology Group at Lehman Brothers and Barclays Capital.
Mr. Yu received a B.A. from Northwestern University and a M.B.A. with honors from the Wharton School at the University of Pennsylvania. He currently serves as a Director of Acino International AG, Arcadia Consumer Healthcare, and Inform Diagnostics and previously served as a Director of Trimb Healthcare.